RE:RE:RE:New weapon against refractory cancers Let's be more positive. UQAM news bulletin is the lowest hanging fruit, along with the paid-for interview. Where they go from here will show how big their ambitions are and how important marketing this is to them. There is a clear focus on cancer at THTX at this moment, it's a good story to tell, obviously first-in-human is the spring board for that. It's actually starting to look like the start on a planned approach to marketing let's see how far it goes. Will it keep going or just fizzle out? It's not a huge commitment of resources to have this run thru AACR, first dosing and onto the earliest meaningful patient data and see what it can achieve.
jfm1330 wrote: These big medias won't do an article about a pre-clinical cancer drug. Comparing these with the UQAM little news bulletin is not right.
Wino115 wrote: THIS is why they need to call business press, magazines and pitch the story. It will be taken up. This is obviously the Montreal connections, but US business press is also always looking for stories like this. I hope the PR side, either Leah or the guy who starts the CC's, calls AP, UPI, Bloomberg, WSJ, NYT Science staff, Stat News, etc... and pitches this complelling story.